SRPT Sarepta Therapeutics, Inc.: institutional ownership and insider trading
350 funds reported holding $2.35B of Sarepta Therapeutics, Inc. in their latest 13F filings; in Q2 2026 funds net bought $51.8M, with 46 new positions and 63 funds selling out; over the last 12 months insiders bought $0 and sold $417K on the open market; over its last four quarters it reported revenue of $1.97B and net income of −$137M.
SRPT revenue and earnings
- Quarter ended Jun 30, 2026: revenue $401M, net income −$4.89M, EPS -0.05
- Quarter ended Mar 31, 2026: revenue $731M, net income $331M, EPS 2.88
- Quarter ended Dec 31, 2025: revenue $443M, net income −$412M, EPS -3.93
- Quarter ended Sep 30, 2025: revenue $399M, net income −$50.6M, EPS -0.50
Famous investors holding SRPT
- Two Sigma (Two Sigma Investments): $82.6M, 0.1% of the portfolio
- Renaissance Technologies (Renaissance Technologies): $20.2M, 0.0% of the portfolio
- Izzy Englander (Millennium Management): $21.4M, 0.0% of the portfolio
- Ray Dalio (Bridgewater Associates): $2.73M, 0.0% of the portfolio
- Ken Griffin (Citadel Advisors): $27.7M, 0.0% of the portfolio
- D. E. Shaw (D. E. Shaw & Co.): $180K, 0.0% of the portfolio
Largest institutional holders of SRPT
- BlackRock, Inc. (BLK) — $341M
- VANGUARD GROUP INC — $254M
- STATE STREET CORP (STT, STT-PG) — $160M
- VANGUARD PORTFOLIO MANAGEMENT LLC — $151M
- TWO SIGMA INVESTMENTS, LP — $82.6M
- VANGUARD CAPITAL MANAGEMENT LLC — $82.5M
- FIRST TRUST ADVISORS LP — $78.5M
- AQR CAPITAL MANAGEMENT LLC — $76.9M
- Nuveen Asset Management, LLC — $63.8M
- GEODE CAPITAL MANAGEMENT, LLC — $49.8M
Recent SRPT insider trades
- Mar 12, 2026: Mayo Stephen sold 7,239 shares ($123K)
- Dec 16, 2025: Estepan Ian Michael sold 13,187 shares ($294K)
- Mar 12, 2025: Nicaise Claude sold 2,491 shares ($248K)
- Dec 12, 2024: Wigzell Hans Lennart Rudolf sold 10,500 shares ($1.31M)
Members of Congress trading SRPT
- Apr 14, 2025: Gilbert Ray Cisneros, Jr. sold $1.00K–$15.0K
5%+ owners
- BlackRock, Inc.: 15.8% (Schedule 13G/A, filed Jul 30, 2026)
- STATE STREET CORPORATION: 8.4% (Schedule 13G, filed Aug 7, 2026)
- Vanguard Portfolio Management: 8.1% (Schedule 13G/A, filed Jul 31, 2026)
- Vanguard Capital Management: 5.1% (Schedule 13G, filed Apr 30, 2026)
- AQR Capital Management, LLC: 5.1% (Schedule 13G/A, filed Aug 13, 2026)
Who owns the most SRPT stock?
The largest institutional holders of Sarepta Therapeutics, Inc. in the latest 13F filings are BlackRock, Inc. (BLK) ($341M), VANGUARD GROUP INC ($254M), STATE STREET CORP (STT, STT-PG) ($160M).
Are insiders buying or selling SRPT?
Over the last 12 months insiders bought $0 and sold $417K of Sarepta Therapeutics, Inc. stock on the open market (SEC Form 4).
Which famous investors own SRPT?
Two Sigma, Renaissance Technologies, Izzy Englander, Ray Dalio, Ken Griffin.
What was SRPT's revenue last quarter?
Sarepta Therapeutics, Inc. reported revenue of $401M for the quarter ended June 30, 2026, with net income of −$4.89M.
Which ETFs hold SRPT?
26 ETFs and mutual funds hold it among their top 100 positions, including XBI, FBT, FGSAX, VSTCX.